Top Biotech Gainers: ZCMD Surges 190%, LABT Advances On Nu-3 Progress, ARWR Hits The Targets
A healthcare sector roundup highlights biotech stock moves. Zhongchao (ZCMD) rose about 192% after a 1-for-3 reverse split for Nasdaq compliance. Lakewood-Amedex (LABT) gained about 83% on positive Nu-3 Phase 2-ready updates. Arrowhead (ARWR) jumped about 19% after SHASTA-3/4 topline results for Plozasiran. Other gainers included MSLE, DRIO, and LBRX.
How this was made
The 30-second read
Why it matters
Traders can treat each name as having a distinct catalyst: compliance-driven reverse split (ZCMD), Nu-3 clinical update (LABT), Phase 3 topline and sNDA plan (ARWR), interim Phase 2 DMD data (MSLE), dilutive capital raise (DRIO), and accelerated pivotal readout timeline (LBRX).
Market read
The article provides same-day, catalyst-specific information that can drive momentum trades and near-term risk management in small/mid-cap biotech.
What to watch
Reverse splits and offerings can increase dilution risk; clinical toplines may still face regulatory and confirmatory-trial uncertainty not addressed in this wrap.
Background
This is a multi-name biotech “top gainers” wrap describing large single-day moves tied to reverse splits, clinical trial updates, and a priced registered direct offering.
Ticker impact
Zhongchao shares surged over 190% after a 1-for-3 reverse split on June 29 to maintain Nasdaq listing compliance.
Near-term volatility likely remains elevated; follow-through depends on whether the company sustains compliance and avoids further dilution.
The article ties the rally directly to the reverse split and compliance framing, but provides no new operating or financial performance datapoint.
Lakewood-Amedex jumped about 83% after reporting positive Nu-3 updates for infected diabetic foot ulcers and antibiotic-resistant infections.
Momentum could persist into additional clinical/regulatory milestones, but expect volatility around further trial details.
The article discloses a specific positive mechanism and Phase 2-ready positioning, which is directly decision-relevant for biotech traders.
Arrowhead rose nearly 19% after topline Phase 3 SHASTA-3 and SHASTA-4 results showed triglyceride reduction and lower acute pancreatitis rates.
Shares may trend higher toward sNDA submission expectations, with pullbacks possible on valuation and remaining regulatory risk.
The article includes primary endpoint success, secondary endpoint success, and a stated sNDA submission plan by year-end.
Satellos Bioscience gained about 15% after reporting encouraging six-month interim TRAILHEAD data for SAT-3247 in adult DMD.
Likely continued speculative bid until more mature data, with headline-driven swings.
The article provides multiple interim outcome improvements and safety commentary, but lacks effect sizes and statistical detail.
DarioHealth rose about 13% after pricing a $23.5 million registered direct offering at $6.80 per share, expected to close around July 23.
Short-term trading may remain choppy around closing and any follow-on guidance; longer-term depends on use of proceeds and burn reduction.
The article discloses the offering size, price, share count, and timing, which are directly actionable for dilution and liquidity modeling.
LB Pharmaceuticals gained about 11% after accelerating LB-102 NOVA-2 topline results to first half of 2027 from second half of 2027.
Potential for continued upside momentum into the earlier readout window, with volatility around interim updates.
The article provides a specific guidance change and downstream FDA pre-NDA timing, which materially affects trading expectations.
Market effects
Reinforces that biotech tape leadership is being driven by Phase 2/3 readouts and schedule changes, not macro factors.
Primarily US-listed biotech sentiment; no explicit cross-region catalyst beyond Nasdaq compliance framing.
Limited, as the catalysts are company-specific clinical and financing events.
Counterpoint
Some rallies may fade if the reverse split and financing headlines dominate fundamentals, or if clinical updates lack the depth needed for durable re-rating.
Key entities
- companyZhongchao Inc.
Reverse split implemented June 29, 2026 to maintain Nasdaq listing compliance; shares surged over 190%.
- companyLakewood-Amedex Biotherapeutics Inc.
Nu-3 antimicrobial update for infected diabetic foot ulcers; shares surged about 83%.
- companyArrowhead Pharmaceuticals, Inc.
Plozasiran Phase 3 SHASTA-3 and SHASTA-4 topline success; sNDA planned by year-end.
- companySatellos Bioscience Inc.
SAT-3247 interim six-month TRAILHEAD data in adult DMD; shares gained about 15%.
- companyDarioHealth Corp.
$23.5 million registered direct offering priced at $6.80; shares rose about 13%.
